45 Neoadjuvant Chemotherapy Use in Elderly Patients

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 24-25

Sami Abujbarah, BA1; Heidi E. Kosiorek, MS2; Jacob B. Hammond, MD3; Patricia A. Cronin, MD4; Sarwat B. Ahmad, MD4; Brenda J. Ernst, MD5; Donald W. Northfelt, MD5; Karen S. Anderson, MD, PhD5; Barbara A. Pockaj, MD4

1Mayo Clinic Alix School of Medicine, Scottsdale, AZ.

2Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ.

3Department of Surgery, Mayo Clinic, Phoenix, AZ.

4Division of Surgical Oncology & Endocrine Surgery, Mayo Clinic, Phoenix, AZ.

5Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.

Background

Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced breast cancer and has been shown to be most effective in the treatment of triple-negative breast cancer (TNBC) and HER2-positive breast cancer. This study characterizes the use of neoadjuvant chemotherapy in elderly patients 65 years (y) and older with early-stage breast cancer from 2005 to 2020.

Materials and Methods

Elderly patients (65 y and older) with TNBC or HER2-postive breast cancer from 2005 to 2020 at a single institution were reviewed. Univariate and multivariate analysis evaluated rates and predictive factors of neoadjuvant chemotherapy treatment use.

Results

Among the 215 patients, approximately a quarter (58; 30.0%) received NAC. The mean age of those who received NAC was significantly lower (70.6 y) than of those who received only adjuvant chemotherapy (72.1 y) or no chemotherapy (76.7 y; P <.001). Those treated with NAC had a significantly larger tumor size (4.3 cm; P <.001) and a higher proportion of locally advanced and advanced stage disease (86.3%; P <.001) than those who received only adjuvant or no chemotherapy. From 2005 through 2020, the proportion of elderly patients receiving neoadjuvant chemotherapy significantly increased, from only 6% receiving NAC in 2005 through 2010, to 50.7% of patients in 2016 through 2020 (Table; P <.0001). This increase was independent of patient age and tumor stage (odds ratio [OR], 11.1; 95% CI. 3.1-39.4; P <.001 for 2011-2015 vs 2005-2010, and OR, 27.7; 95% CI, 8.1-95.3; P <.001 for 2016-2020 vs 2005-2010 reference group). Changes in the chemotherapeutic agents used also occurred over this period, with a significant decrease in the usage of anthracycline from 2005 through 2010 (18.6%) compared with 2016 through 2020 (0.0%; P <.0001). There was no significant difference in hospitalization or chemotherapy dose reduction rates in patients receiving NAC compared with those who received only adjuvant chemotherapy.

TABLE. Chemotherapy Treatment Trends, 2005-2020

TABLE. Chemotherapy Treatment Trends, 2005-2020

Conclusions

NAC is becoming more widely used in elderly patients with HER2-postive and triple-negative tumors, independent of age and tumor stage, with no increased risk of chemotherapy complications.

Expert Commentary

Expert Commentary

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content